Revisiting AJCC TNM staging for renal cell carcinoma: quest for improvement.
作者信息
Swami Umang, Nussenzveig Roberto H, Haaland Benjamin, Agarwal Neeraj
机构信息
Department of Hematology, Oncology and Blood and Marrow Transplantation, The Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics, Iowa City, IA, USA.
Division of Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
出版信息
Ann Transl Med. 2019 Mar;7(Suppl 1):S18. doi: 10.21037/atm.2019.01.50.
Abstract
摘要
相似文献
1
Revisiting AJCC TNM staging for renal cell carcinoma: quest for improvement.重新审视美国癌症联合委员会（AJCC）肾细胞癌TNM分期：寻求改进
Ann Transl Med. 2019 Mar;7(Suppl 1):S18. doi: 10.21037/atm.2019.01.50.
2
A comparison of the 7th and 8th editions of the AJCC staging system in terms of predicting recurrence and survival in patients with papillary thyroid carcinoma.第 7 版和第 8 版 AJCC 分期系统在预测甲状腺乳头状癌患者复发和生存方面的比较。
Oral Oncol. 2018 Dec;87:158-164. doi: 10.1016/j.oraloncology.2018.11.003. Epub 2018 Nov 9.
3
Confirmation of the eighth edition of the AJCC/UICC TNM staging system for HPV-mediated oropharyngeal cancer in Japan.日本对AJCC/UICC TNM分期系统第八版用于人乳头瘤病毒介导的口咽癌的确认。
Int J Clin Oncol. 2017 Aug;22(4):682-689. doi: 10.1007/s10147-017-1107-0. Epub 2017 Mar 7.
4
Staging of hepatocellular carcinoma: assessment of the Japanese TNM and AJCC/UICC TNM systems in a cohort of 13,772 patients in Japan.肝细胞癌的分期：对日本13772例患者队列中日本TNM和AJCC/UICC TNM系统的评估
Ann Surg. 2007 Jun;245(6):909-22. doi: 10.1097/01.sla.0000254368.65878.da.
5
The applicability of new TNM classification for humanpapilloma virus-related oropharyngeal cancer in the 8th edition of the AJCC/UICC TNM staging system in Japan: A single-centre study.日本第8版美国癌症联合委员会/国际抗癌联盟（AJCC/UICC）TNM分期系统中新型TNM分类对人乳头瘤病毒相关口咽癌的适用性：一项单中心研究。
Auris Nasus Larynx. 2018 Jun;45(3):558-565. doi: 10.1016/j.anl.2017.07.010. Epub 2017 Jul 29.
6
Assessing a modified-AJCC TNM staging system in the New South Wales Cancer Registry, Australia.评估澳大利亚新南威尔士癌症登记处的改良-AJCC TNM 分期系统。
BMC Cancer. 2019 Aug 28;19(1):850. doi: 10.1186/s12885-019-6062-x.
7
Staging renal cell carcinoma with helical CT: the revised 1997 AJCC and UICC TNM criteria.使用螺旋CT对肾细胞癌进行分期：1997年修订的美国癌症联合委员会（AJCC）和国际抗癌联盟（UICC）TNM标准
Crit Rev Comput Tomogr. 2003;44(4):229-49. doi: 10.3109/bctg.44.4.229.249.
8
Pathologic staging of renal cell carcinoma: significance of tumor classification with the 1997 TNM staging system.肾细胞癌的病理分期：1997年TNM分期系统对肿瘤分类的意义。
Cancer. 2001 Jan 15;91(2):354-61. doi: 10.1002/1097-0142(20010115)91:2<354::aid-cncr1009>3.0.co;2-9.
9
A comparison between the sixth and seventh editions of the UICC/AJCC staging system for nasopharyngeal carcinoma in a Chinese cohort.中国队列中 UICC/AJCC 鼻咽癌分期系统第六版与第七版的比较。
PLoS One. 2014 Dec 23;9(12):e116261. doi: 10.1371/journal.pone.0116261. eCollection 2014.
引用本文的文献
1
Development of a prognostic risk model for clear cell renal cell carcinoma by systematic evaluation of DNA methylation markers: an update after ISUP/WHO 2022 classification.通过对DNA甲基化标志物的系统评估建立透明细胞肾细胞癌的预后风险模型：ISUP/WHO 2022分类后的更新
J Pathol Clin Res. 2025 Sep;11(5):e70030. doi: 10.1002/2056-4538.70030.
2
[A retrospective matching study of partial nephrectomy and radical nephrectomy for pathological T3a stage renal cell carcinoma].[病理T3a期肾细胞癌行部分肾切除术与根治性肾切除术的回顾性匹配研究]
Beijing Da Xue Xue Bao Yi Xue Ban. 2025 Aug 18;57(4):704-710. doi: 10.19723/j.issn.1671-167X.2025.04.012.
3
Survival and treatment of stage IV renal cell carcinoma in academic non-academic medical centers.学术性与非学术性医疗中心中IV期肾细胞癌的生存与治疗
World J Nephrol. 2025 Jun 25;14(2):103923. doi: 10.5527/wjn.v14.i2.103923.
4
Association of Histologic Growth Patterns and Some Histopathologic Features in Clear Cell Renal Cell Carcinoma with Patient's Survival after Nephrectomy: A Cross-Sectional Study.透明细胞肾细胞癌的组织学生长模式及一些组织病理学特征与肾切除术后患者生存率的相关性：一项横断面研究
Iran J Pathol. 2025 Spring;20(2):198-206. doi: 10.30699/ijp.2025.2033228.3319. Epub 2025 Mar 10.
5
Trends in kidney cancer: exploring the impact of sex and age on stage of disease, and prognosis during the past three decades in Denmark-a DaRenCa study.肾癌趋势：丹麦一项DaRenCa研究探索过去三十年中性别和年龄对疾病分期及预后的影响
Eur J Epidemiol. 2025 May 14. doi: 10.1007/s10654-025-01236-7.
6
Intra- and Peritumoral CT-Based Radiomics for Assessing Pathologic T-Staging in Clear Cell Renal Cell Carcinoma: A Multicenter Study.基于CT的肾透明细胞癌瘤内及瘤周放射组学评估病理T分期：一项多中心研究
Ann Surg Oncol. 2025 Jun;32(6):4550-4561. doi: 10.1245/s10434-025-17111-4. Epub 2025 Mar 19.
7
The Current State of the Diagnoses and Treatments for Clear Cell Renal Cell Carcinoma.透明细胞肾细胞癌的诊断与治疗现状
Cancers (Basel). 2024 Dec 1;16(23):4034. doi: 10.3390/cancers16234034.
8
Demographic Characteristics and Treatment Outcomes of Advanced Renal Cell Carcinoma With Clear Cell Histology: A Single-Center Experience From India.透明细胞组织学类型的晚期肾细胞癌的人口统计学特征及治疗结果：来自印度的单中心经验
Cureus. 2024 Jun 8;16(6):e61978. doi: 10.7759/cureus.61978. eCollection 2024 Jun.
9
Development and validation of prognostic nomograms for adult with papillary renal cell carcinoma: A retrospective study.开发和验证成人肾乳头状细胞癌预后列线图：一项回顾性研究。
Clinics (Sao Paulo). 2024 May 7;79:100374. doi: 10.1016/j.clinsp.2024.100374. eCollection 2024.
10
MOICS, a novel classier deciphering immune heterogeneity and aid precise management of clear cell renal cell carcinoma at multiomics level.MOICS是一种新型分类器，可在多组学水平上解读免疫异质性并辅助对肾透明细胞癌进行精准管理。
Cancer Biol Ther. 2024 Dec 31;25(1):2345977. doi: 10.1080/15384047.2024.2345977. Epub 2024 Apr 24.
本文引用的文献
1
Modification of American Joint Committee on cancer prognostic groups for renal cell carcinoma.美国癌症联合委员会肾癌预后分组的修正。
Cancer Med. 2018 Nov;7(11):5431-5438. doi: 10.1002/cam4.1790. Epub 2018 Oct 10.
2
Nomograms for predicting long-term overall survival and disease-specific survival of patients with clear cell renal cell carcinoma.预测透明细胞肾细胞癌患者长期总生存和疾病特异性生存的列线图。
Onco Targets Ther. 2018 Sep 6;11:5535-5544. doi: 10.2147/OTT.S171881. eCollection 2018.
3
Personalized Management of Advanced Kidney Cancer.晚期肾癌的个体化管理
Am Soc Clin Oncol Educ Book. 2018 May 23;38:330-341. doi: 10.1200/EDBK_201215.
4
Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): An Abridged Explanation and Elaboration.报告肿瘤标志物预后研究推荐（REMARK）：摘要解释和详细说明。
J Natl Cancer Inst. 2018 Aug 1;110(8):803-811. doi: 10.1093/jnci/djy088.
5
Prognostic factors and prognostic models for renal cell carcinoma: a literature review.肾细胞癌的预后因素和预后模型：文献综述。
World J Urol. 2018 Dec;36(12):1943-1952. doi: 10.1007/s00345-018-2309-4. Epub 2018 Apr 30.
6
The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma.癌症基因组图谱对肾细胞癌的全面分子特征分析。
Cell Rep. 2018 Apr 3;23(1):313-326.e5. doi: 10.1016/j.celrep.2018.03.075.
7
External validation of clinical prediction models using big datasets from e-health records or IPD meta-analysis: opportunities and challenges.利用电子健康记录或个体患者数据（IPD）荟萃分析的大数据集对临床预测模型进行外部验证：机遇与挑战
BMJ. 2016 Jun 22;353:i3140. doi: 10.1136/bmj.i3140.
8
American Joint Committee on Cancer acceptance criteria for inclusion of risk models for individualized prognosis in the practice of precision medicine.美国癌症联合委员会关于在精准医学实践中纳入个性化预后风险模型的纳入标准。
CA Cancer J Clin. 2016 Sep;66(5):370-4. doi: 10.3322/caac.21339. Epub 2016 Jan 19.
9
Editorial comment.编辑评论。
J Urol. 2011 Nov;186(5):1777-8. doi: 10.1016/j.juro.2011.07.127. Epub 2011 Sep 25.
10
Prognostic factors and predictive models in renal cell carcinoma: a contemporary review.肾细胞癌的预后因素和预测模型：当代综述。
Eur Urol. 2011 Oct;60(4):644-61. doi: 10.1016/j.eururo.2011.06.041. Epub 2011 Jun 30.
Zotero 插件